# Radio-antibody & radio-ADC

Source: https://onco.cc/technologies/radioimmunotherapy/  
OnCo record `radioimmunotherapy` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Attaching a radioactive atom to an antibody, so an ADC's targeting is used to deliver radiation instead of chemotherapy.

## Summary

90Y-ibritumomab (Zevalin) and 131I-tositumomab proved the concept in lymphoma but were commercially abandoned. Renewed interest: 225Ac-labelled antibodies to PSMA (J591), CD33 (lintuzumab), DLL3, HER2, and 177Lu-labelled antibodies. Long antibody half-life is both a dosimetry advantage and a marrow-toxicity problem; pretargeting and fragment approaches address it.

## Fields

- Kind: Technology
- Status: phase-2
- Last checked: 2026-09-04
- Tags: frontier
- Principle: A chelator-conjugated antibody or fragment carries 177Lu, 225Ac, 212Pb, or 131I.
- Strengths: Any ADC target becomes a radiation target; Bystander crossfire independent of payload chemistry
- Limitations: Marrow dose from circulating antibody; Manufacturing complexity

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Radioimmunotherapy
- Wikipedia: https://en.wikipedia.org/wiki/Radioimmunotherapy

## Connected records

- ideas: [Alpha radioligands after ADC failure](https://onco.cc/ideas/idea-alpha-after-adc/), [CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy](https://onco.cc/ideas/idea-caix-theranostics/), [Efflux-agnostic therapy for mesenchymal TNBC](https://onco.cc/ideas/idea-efflux-agnostic/), [Focused-ultrasound BBB opening to deliver ADCs and radioligands to glioma](https://onco.cc/ideas/idea-fus-plus-adc-glioma/)
- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Auger-electron therapy](https://onco.cc/technologies/auger-electron-therapy/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Targeted alpha therapy](https://onco.cc/technologies/targeted-alpha-therapy/), [Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)](https://onco.cc/technologies/therapy-isotope-supply-chain/)
- targets: [CD33](https://onco.cc/targets/cd33/), [DLL3](https://onco.cc/targets/dll3/), [HER2](https://onco.cc/targets/her2/), [PSMA](https://onco.cc/targets/psma/)
- companies: [Abdera Therapeutics](https://onco.cc/companies/abdera-therapeutics/), [Actinium Pharmaceuticals](https://onco.cc/companies/actinium-pharmaceuticals/), [Convergent Therapeutics](https://onco.cc/companies/convergent-therapeutics/)
- journals: [Cancer biotherapy & radiopharmaceuticals](https://onco.cc/journals/cancer-biotherapy-and-radiopharmaceuticals/)
- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- roadmaps: [ADC roadmap: from Mylotarg to bispecific and dual-payload ADCs](https://onco.cc/roadmaps/adc-generations/), [Radiopharmaceutical roadmap: iodine → lutetium → actinium](https://onco.cc/roadmaps/radiopharma-roadmap/), [Radiotherapy roadmap: X-rays → shaped beams → fewer fractions, particles and FLASH](https://onco.cc/roadmaps/radiation-roadmap/), [TROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET](https://onco.cc/roadmaps/trop2-adc-roadmap/)
- drugs: [Ibritumomab tiuxetan](https://onco.cc/drugs/ibritumomab-tiuxetan/), [Iomab-B](https://onco.cc/drugs/iomab-b/)
- trials: [Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia](https://onco.cc/trials/nct02665065/)

---
JSON: https://onco.cc/api/v1/entities/radioimmunotherapy.json